Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo.
Bottom Line: Busulfan has been widely used to treat CML.Moreover, a series of loss-of-function and gain-of-function experiments further indicated that busulfan may have its anti-osteosarcoma effect by upregulating the microRNA-200 (miR-200) family which subsequently downregulated its target genes ZEB1 and ZEB2.Taken together, our data suggest that busulfan may have an anti-osteosarcoma effect through downregulating ZEB1 and ZEB2 through activating the miR-200 family, highlighting a possibility of using busulfan as a novel therapy for osteosarcoma.
Affiliation: 169th Hospital, School of Medicine, Hunan Normal University, Changsha, China.Show MeSH
Related in: MedlinePlus
Mentions: Two osteosarcoma cell lines (U2OS and MG-63) were treated with busulfan for 48 h in culture, and the viable cells were detected by Trypan blue exclusion test. We found that busulfan reduced the cancer cell viability in a dose-dependent manner (Fig. 1a). As a concentration of 150 μM potentially decreased cell viability by more than 70% in both lines, it was thus applied in the following experiments.
Affiliation: 169th Hospital, School of Medicine, Hunan Normal University, Changsha, China.